Role of long noncoding RNA taurine‐upregulated gene 1 in cancers

• Published in: Molecular medicine (Cambridge, Mass.) Vol. 27; no. 1; pp. 51 - 17
• Main Authors: Da, Miao, Zhuang, Jing, Zhou, Yani, Qi, Quan, Han, Shuwen
• Format: Journal Article
• Language: English
• Published: England BioMed Central 26.05.2021; BMC
• Subjects: Angiogenesis; Animals; Apoptosis; Apoptosis - genetics; Biomarker; Biomarkers, Tumor; Bladder cancer; Bone cancer; Breast cancer; Cancer; Cell Cycle; Cell division; Cell growth; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy; Competitive endogenous RNA (ceRNA); Cyclin-dependent kinases; Disease Susceptibility; Drug resistance; Epigenetics; Gene Expression Regulation, Neoplastic - drug effects; Humans; Kidney cancer; Kinases; Long non-coding RNA (lncRNA); Lung cancer; Metastasis; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms - genetics; Neoplasms - metabolism; Neoplasms - pathology; Neoplasms - therapy; Neovascularization, Pathologic - genetics; Neovascularization, Pathologic - metabolism; Pancreatic cancer; Prostate cancer; Review; RNA, Long Noncoding - genetics; Signal Transduction; Taurine‐upregulated gene 1 (TUG1); Vascular endothelial growth factor; Taurine‐upregulated gene 1 (TUG1); Biomarker; Competitive endogenous RNA (ceRNA); Long non-coding RNA (lncRNA); Cancer
• ISSN: 1076-1551; 1528-3658; 1528-3658
• DOI: 10.1186/s10020-021-00312-4

Long non-coding RNAs (lncRNAs) are a group of non-protein coding RNAs with a length of more than 200 bp. The lncRNA taurine up-regulated gene 1 ( TUG1 ) is abnormally expressed in many human malignant cancers, where it acts as a competitive endogenous RNA (ceRNA), regulating gene expression by specifically sponging its corresponding microRNAs. In the present review, we summarised the current understanding of the role of lncRNA TUG1 in cancer cell proliferation, metastasis, angiogenesis, chemotherapeutic drug resistance, radiosensitivity, cell regulation, and cell glycolysis, as well as highlighting its potential application as a clinical biomarker or therapeutic target for malignant cancer. This review provides the basis for new research directions for lncRNA TUG1 in cancer prevention, diagnosis, and treatment.